Myvizhi Esai Selvan1, Marjorie G Zauderer2, Charles M Rudin2, Siân Jones3, Semanti Mukherjee2, Kenneth Offit2, Kenan Onel1, Gad Rennert4, Victor E Velculescu3, Steven M Lipkin5, Robert J Klein1, Zeynep H Gümüş6. 1. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit National Israeli Cancer Control Center, Haifa, Israel. 5. Departments of Medicine and Genetic Medicine, Weill Cornell Medical College, New York, New York. 6. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: zeynep.gumus@mssm.edu.
Abstract
INTRODUCTION: Lung cancer is the leading cause of cancer deaths in the world, and lung adenocarcinoma (LUAD) is its most prevalent subtype. Symptoms are often found in advanced disease in which treatment options are limited. Identifying genetic risk factors will enable better identification of high-risk individuals. METHODS: To identify LUAD risk genes, we performed a case-control association study for gene-level burden of rare, deleterious variants (RDVs) in germline whole-exome sequencing data of 1083 patients with LUAD and 7650 controls, split into discovery and validation cohorts. Of these, we performed whole-exome sequencing on 97 patients and acquired the rest from multiple public databases. We annotated all rare variants for pathogenicity conservatively, using the guidelines of the American College of Medical Genetics and Genomics and ClinVar curation, and investigated gene-level RDV burden using penalized logistic regression. All statistical tests were two-sided. RESULTS: We discovered and replicated the finding that the burden of germline ATM RDVs was significantly higher in patients with LUAD versus controls (combined cohort OR = 4.6; p = 1.7e-04; 95% confidence interval = 2.2-9.5; 1.21% of cases; 0.24% of controls). Germline ATM RDVs were also enriched in an independent clinical cohort of 1594 patients from the MSK-IMPACT study (0.63%). In addition, we observed that an Ashkenazi Jewish (AJ) founder ATM variant, rs56009889, was statistically significantly more frequent in AJ cases versus AJ controls in our cohort (combined AJ cohort OR = 2.7, p = 6.9e-03, 95% confidence interval = 1.3-5.3). CONCLUSIONS: Our results indicate that ATM is a moderate-penetrance LUAD risk gene and that LUAD may be a part of the ATM-related cancer syndrome spectrum. Individuals with ATM RDVs are at an elevated LUAD risk and can benefit from increased surveillance (particularly computed tomography scanning), early detection, and chemoprevention programs, improving prognosis.
INTRODUCTION: Lung cancer is the leading cause of cancer deaths in the world, and lung adenocarcinoma (LUAD) is its most prevalent subtype. Symptoms are often found in advanced disease in which treatment options are limited. Identifying genetic risk factors will enable better identification of high-risk individuals. METHODS: To identify LUAD risk genes, we performed a case-control association study for gene-level burden of rare, deleterious variants (RDVs) in germline whole-exome sequencing data of 1083 patients with LUAD and 7650 controls, split into discovery and validation cohorts. Of these, we performed whole-exome sequencing on 97 patients and acquired the rest from multiple public databases. We annotated all rare variants for pathogenicity conservatively, using the guidelines of the American College of Medical Genetics and Genomics and ClinVar curation, and investigated gene-level RDV burden using penalized logistic regression. All statistical tests were two-sided. RESULTS: We discovered and replicated the finding that the burden of germline ATM RDVs was significantly higher in patients with LUAD versus controls (combined cohort OR = 4.6; p = 1.7e-04; 95% confidence interval = 2.2-9.5; 1.21% of cases; 0.24% of controls). Germline ATM RDVs were also enriched in an independent clinical cohort of 1594 patients from the MSK-IMPACT study (0.63%). In addition, we observed that an Ashkenazi Jewish (AJ) founder ATM variant, rs56009889, was statistically significantly more frequent in AJ cases versus AJ controls in our cohort (combined AJ cohort OR = 2.7, p = 6.9e-03, 95% confidence interval = 1.3-5.3). CONCLUSIONS: Our results indicate that ATM is a moderate-penetrance LUAD risk gene and that LUAD may be a part of the ATM-related cancer syndrome spectrum. Individuals with ATM RDVs are at an elevated LUAD risk and can benefit from increased surveillance (particularly computed tomography scanning), early detection, and chemoprevention programs, improving prognosis.
Authors: Kuan-Lin Huang; R Jay Mashl; Yige Wu; Deborah I Ritter; Jiayin Wang; Clara Oh; Marta Paczkowska; Sheila Reynolds; Matthew A Wyczalkowski; Ninad Oak; Adam D Scott; Michal Krassowski; Andrew D Cherniack; Kathleen E Houlahan; Reyka Jayasinghe; Liang-Bo Wang; Daniel Cui Zhou; Di Liu; Song Cao; Young Won Kim; Amanda Koire; Joshua F McMichael; Vishwanathan Hucthagowder; Tae-Beom Kim; Abigail Hahn; Chen Wang; Michael D McLellan; Fahd Al-Mulla; Kimberly J Johnson; Olivier Lichtarge; Paul C Boutros; Benjamin Raphael; Alexander J Lazar; Wei Zhang; Michael C Wendl; Ramaswamy Govindan; Sanjay Jain; David Wheeler; Shashikant Kulkarni; John F Dipersio; Jüri Reimand; Funda Meric-Bernstam; Ken Chen; Ilya Shmulevich; Sharon E Plon; Feng Chen; Li Ding Journal: Cell Date: 2018-04-05 Impact factor: 41.582
Authors: Erin M Parry; Dustin L Gable; Susan E Stanley; Sara E Khalil; Valentin Antonescu; Liliana Florea; Mary Armanios Journal: J Thorac Oncol Date: 2017-08-24 Impact factor: 15.609
Authors: Zsofia K Stadler; Peter Thom; Mark E Robson; Jeffrey N Weitzel; Noah D Kauff; Karen E Hurley; Vincent Devlin; Bert Gold; Robert J Klein; Kenneth Offit Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: Nicholas J Roberts; Yuchen Jiao; Jun Yu; Levy Kopelovich; Gloria M Petersen; Melissa L Bondy; Steven Gallinger; Ann G Schwartz; Sapna Syngal; Michele L Cote; Jennifer Axilbund; Richard Schulick; Syed Z Ali; James R Eshleman; Victor E Velculescu; Michael Goggins; Bert Vogelstein; Nickolas Papadopoulos; Ralph H Hruban; Kenneth W Kinzler; Alison P Klein Journal: Cancer Discov Date: 2011-12-29 Impact factor: 39.397
Authors: Charles Lu; Mingchao Xie; Michael C Wendl; Jiayin Wang; Michael D McLellan; Mark D M Leiserson; Kuan-Lin Huang; Matthew A Wyczalkowski; Reyka Jayasinghe; Tapahsama Banerjee; Jie Ning; Piyush Tripathi; Qunyuan Zhang; Beifang Niu; Kai Ye; Heather K Schmidt; Robert S Fulton; Joshua F McMichael; Prag Batra; Cyriac Kandoth; Maheetha Bharadwaj; Daniel C Koboldt; Christopher A Miller; Krishna L Kanchi; James M Eldred; David E Larson; John S Welch; Ming You; Bradley A Ozenberger; Ramaswamy Govindan; Matthew J Walter; Matthew J Ellis; Elaine R Mardis; Timothy A Graubert; John F Dipersio; Timothy J Ley; Richard K Wilson; Paul J Goodfellow; Benjamin J Raphael; Feng Chen; Kimberly J Johnson; Jeffrey D Parvin; Li Ding Journal: Nat Commun Date: 2015-12-22 Impact factor: 14.919
Authors: Jian Sang; Tongwu Zhang; Jung Kim; Mengying Li; Angela C Pesatori; Dario Consonni; Lei Song; Jia Liu; Wei Zhao; Phuc H Hoang; Dave S Campbell; James Feng; Monica E D'Arcy; Naoise Synnott; Yingxi Chen; Zeni Wu; Bin Zhu; Xiaohong R Yang; Kevin M Brown; Jiyeon Choi; Jianxin Shi; Maria Teresa Landi Journal: Hum Mol Genet Date: 2022-10-10 Impact factor: 5.121
Authors: Semanti Mukherjee; Chaitanya Bandlamudi; Matthew D Hellmann; Yelena Kemel; Esther Drill; Hira Rizvi; Kaitlyn Tkachuk; Aliya Khurram; Michael F Walsh; Marjorie G Zauderer; Diana Mandelker; Sabine Topka; Ahmet Zehir; Preethi Srinivasan; Myvizhi Esai Selvan; Maria I Carlo; Karen A Cadoo; Alicia Latham; Jada G Hamilton; Ying L Liu; Steven M Lipkin; Sami Belhadj; Gareth L Bond; Zeynep H Gümüş; Robert J Klein; Marc Ladanyi; David B Solit; Mark E Robson; David R Jones; Mark G Kris; Joseph Vijai; Zsofia K Stadler; Christopher I Amos; Barry S Taylor; Michael F Berger; Charles M Rudin; Kenneth Offit Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Todd Lencz; Jin Yu; Raiyan Rashid Khan; Erin Flaherty; Shai Carmi; Max Lam; Danny Ben-Avraham; Nir Barzilai; Susan Bressman; Ariel Darvasi; Judy H Cho; Lorraine N Clark; Zeynep H Gümüş; Joseph Vijai; Robert J Klein; Steven Lipkin; Kenneth Offit; Harry Ostrer; Laurie J Ozelius; Inga Peter; Anil K Malhotra; Tom Maniatis; Gil Atzmon; Itsik Pe'er Journal: Neuron Date: 2021-03-22 Impact factor: 17.173
Authors: Riyue Bao; Anita Ng; Mark Sasaki; Myvizhi Esai Selvan; Alyna Katti; Hyesan Lee; Lei Huang; Andrew D Skol; Cinzia Lavarino; Hector Salvador; Robert J Klein; Zeynep H Gümüş; Jaume Mora; Kenan Onel Journal: Cancer Prev Res (Phila) Date: 2021-01-08
Authors: Yanhong Liu; Jun Xia; James McKay; Spiridon Tsavachidis; Xiangjun Xiao; Margaret R Spitz; Chao Cheng; Jinyoung Byun; Wei Hong; Yafang Li; Dakai Zhu; Zhuoyi Song; Susan M Rosenberg; Michael E Scheurer; Farrah Kheradmand; Claudio W Pikielny; Christine M Lusk; Ann G Schwartz; Ignacio I Wistuba; Michael H Cho; Edwin K Silverman; Joan Bailey-Wilson; Susan M Pinney; Marshall Anderson; Elena Kupert; Colette Gaba; Diptasri Mandal; Ming You; Mariza de Andrade; Ping Yang; Triantafillos Liloglou; Michael P A Davies; Jolanta Lissowska; Beata Swiatkowska; David Zaridze; Anush Mukeria; Vladimir Janout; Ivana Holcatova; Dana Mates; Jelena Stojsic; Ghislaine Scelo; Paul Brennan; Geoffrey Liu; John K Field; Rayjean J Hung; David C Christiani; Christopher I Amos Journal: NPJ Precis Oncol Date: 2021-02-16